{"schema_version":"alpha-company-profile-public-v2","slug":"elicio-therapeutics-inc","canonical_url":"https://registry.alpha.ac/companies/elicio-therapeutics-inc","published_on":"2026-11-06T04:47:02.533883+00:00","last_reviewed_on":"2026-11-06T04:47:02.533883+00:00","identity":{"legal_name":"Elicio Therapeutics, Inc.","display_name":"Elicio Therapeutics, Inc.","headline":"Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases.","description":"Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers.","ten_second_view":"This Company Profile publishes only Alpha's canonical identity and evidence-backed public leadership records. Unavailable fields are not inferred.","legal_form":"Not publicly asserted","incorporation":"Not publicly asserted","headquarters":"US","headquarters_address":{"locality":"Not publicly asserted","region":null,"country":"US"},"operating_presence":["US"],"website":"","cik":"0001601485","logo":"https://cdn.brandfetch.io/ticker/eltx/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","logo_source":"brandfetch","profile_mark":{"src":"https://cdn.brandfetch.io/ticker/eltx/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","alt":"Elicio Therapeutics, Inc. logo","width":256,"height":256,"source":"brandfetch"}},"entity_status":{"ownership_type":"unknown","listing_status":"listed","label":"Public listing published","explanation":"The canonical public record includes at least one active security listing.","source_id":"alpha-canonical-company-record","reviewed_on":"2026-11-06T04:47:02.533883+00:00"},"security_listings":[{"ticker":"ELTX","exchange":"NASDAQ","exchange_display":"NASDAQ","mic":"XNAS","currency":"Unavailable","security_type":"equity","listing_status":"active","is_primary":true,"source_id":"alpha-canonical-company-record"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market data is not published in this Company Profile."},"profile_tags":["Canonical identity","Public leadership"],"trust_summary":"Canonical identity published; broader company intelligence is not asserted.","facts":[{"label":"Legal name","value":"Elicio Therapeutics, Inc.","source_id":"alpha-canonical-company-record"},{"label":"Country","value":"US","source_id":"alpha-canonical-company-record"},{"label":"Sector","value":"Healthcare","source_id":"alpha-canonical-company-record"},{"label":"Industry","value":"Biotechnology","source_id":"alpha-canonical-company-record"}],"operating_model":{"eyebrow":"Operating record","title":"Published operating structure","units":[]},"governance":{"summary":"Only current, confirmed leadership roles with public evidence are included in the canonical projection.","boundary":"Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","disclosures":[]},"alpha_opinion":{"status":"Not published","label":"No Alpha opinion published","explanation":"This identity record is not an Alpha rating, score, or investment opinion."},"report":{"status":"Not published","label":"No governed report published","explanation":"No governed company report is attached to this profile.","href":null},"actions":[],"related_records":[],"evidence":[{"id":"alpha-canonical-company-record","label":"Alpha canonical company public projection","href":"/api/public/companies/elicio-therapeutics-inc","source_type":"canonical_identity","supports":["Company identity","Published leadership","Entity status boundary"],"status":"published","reviewed_on":"2026-11-06T04:47:02.533883+00:00"}],"permissions":[{"label":"Public retrieval","allowed":true},{"label":"Agent retrieval","allowed":true},{"label":"Redistribution","allowed":false},{"label":"Model training","allowed":false},{"label":"Relationship pathfinding","allowed":false},{"label":"Direct contact","allowed":false}],"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"financials":{"kind":"financials","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"ownership":{"kind":"ownership","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented. 13F and N-PX are not beneficial ownership and are never projected here.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"trust":{"schema_version":"alpha-profile-trust-v1","verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":19,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"aggregation":{"schema_version":"alpha-claim-aggregation-v1","published_claim_count":19,"under_review_claim_count":1,"owner_supplied_claim_count":0,"evidence_record_count":3,"distinct_source_count":2,"conflicts":[],"conflict_count":0,"headline_conflict_count":0,"internal_review_conflict_count":0,"contradiction_types":[],"headline_conflict_types":[],"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":19,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"coverage":{"schema_version":"alpha-coverage-metric-v1","published_claims":19,"corroborated_claims":0,"sources":3,"distinct_sources":2,"role_claims":0,"last_reviewed_at":"2026-11-06T04:47:02.533883+00:00","observed_at":"2026-11-06T04:47:02.533883+00:00","freshness_days":0}},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"}},"projection":{"schema_version":"alpha-profile-projection-v5","entity":{"kind":"company","slug":"elicio-therapeutics-inc","canonical_url":"https://registry.alpha.ac/companies/elicio-therapeutics-inc"},"publication":{"published_at":"2026-11-06T04:47:02.533883+00:00","last_reviewed_at":"2026-11-06T04:47:02.533883+00:00","as_of":"2026-11-06T04:47:02.533883+00:00"},"representations":{"html":{"href":"https://registry.alpha.ac/companies/elicio-therapeutics-inc","media_type":"text/html"},"json":{"href":"https://registry.alpha.ac/api/public/companies/elicio-therapeutics-inc","media_type":"application/json"},"markdown":{"href":"https://registry.alpha.ac/companies/elicio-therapeutics-inc.md","media_type":"text/markdown"},"structured_data":{"embedded":true,"media_type":"application/ld+json"},"share_image":null},"permissions":{"public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false}},"canonical_profile":{"schema_version":"alpha-company-profile-public-v1","slug":"elicio-therapeutics-inc","canonical_url":"https://registry.alpha.ac/companies/elicio-therapeutics-inc","as_of":"2026-11-06T04:47:02.533883+00:00","last_reviewed_at":"2026-11-06T04:47:02.533883+00:00","identity":{"legal_name":"Elicio Therapeutics, Inc.","display_name":"Elicio Therapeutics, Inc.","description":"Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing muta","jurisdiction":null,"country":"US","sector":"Healthcare","industry":"Biotechnology","website":null,"website_provenance":null,"logo_url":null,"logo_media":null,"status":"active","cik":"0001601485","entity_subtype":null,"legal_entity_status":null},"security_listings":[{"mic":"XNAS","ticker":"ELTX","currency":null,"exchange":"NASDAQ","sort_key":0,"valid_to":null,"confidence":0.95,"is_primary":true,"listing_id":"fead1561-588c-4f81-b9f3-a032436d0b8b","source_url":"https://www.sec.gov/files/company_tickers_exchange.json","valid_from":null,"observed_at":"2026-07-11T00:28:32+00:00","source_name":"sec_company_tickers_exchange","source_tier":1,"exchange_name":"NASDAQ","security_type":"equity","listing_status":"active","last_checked_at":"2026-09-02T01:48:40.989053+00:00"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market observations are unpublished. Listing identity remains available from the governed source set."},"index_memberships":[],"index_membership_history":[],"index_membership_contract":{"schema_version":"alpha-index-membership-public-v1","as_of_date":"2026-11-06","tracked_universe_complete":false,"permissions":{"public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false},"limitations":["Only source-backed memberships with an explicit public redistribution basis are returned.","Absence from Alpha tracked indices does not establish absence from every market index.","Provider announcements and effective membership are represented as distinct states.","Alpha AI 100 is not published as a current public index membership."]},"leadership":{"board":[{"person_slug":"allen-r-nissenson-m-d","display_name":"Allen R. Nissenson, M.D.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2023-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Elicio Therapeutics, Inc. DEF 14A 2026-10-09","source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000061-index.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-10-09","last_checked_at":"2026-10-11T00:14:07.386956+00:00"},"headshot_url":null},{"person_slug":"carol-ashe","display_name":"Carol Ashe","role_category":"director","title":"Director","committee":"Audit; Compensation · Chair; Nominating and Governance","is_board_chair":false,"is_independent":true,"start_date":"2023-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Elicio Therapeutics, Inc. DEF 14A 2026-10-09","source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000061-index.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-10-09","last_checked_at":"2026-10-11T00:14:07.386956+00:00"},"headshot_url":null},{"person_slug":"jay-venkatesan-ser","display_name":"Jay Venkatesan","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2023-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Elicio Therapeutics, Inc. DEF 14A 2026-10-09","source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000061-index.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-10-09","last_checked_at":"2026-10-11T00:14:07.386956+00:00"},"headshot_url":null},{"person_slug":"julian-adams-ph-d","display_name":"Julian Adams, Ph.D.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2023-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Elicio Therapeutics, Inc. DEF 14A 2026-10-09","source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000061-index.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-10-09","last_checked_at":"2026-10-11T00:14:07.386956+00:00"},"headshot_url":null},{"person_slug":"robert-connelly","display_name":"Robert Connelly","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2023-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Elicio Therapeutics, Inc. DEF 14A 2026-10-09","source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000061-index.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-10-09","last_checked_at":"2026-10-11T00:14:07.386956+00:00"},"headshot_url":null},{"person_slug":"robert-r-ruffolo-jr-ph-d","display_name":"Robert R. Ruffolo, Jr., Ph.D.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2023-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Elicio Therapeutics, Inc. DEF 14A 2026-10-09","source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000061-index.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-10-09","last_checked_at":"2026-10-11T00:14:07.386956+00:00"},"headshot_url":null},{"person_slug":"yekaterina-katie-chudnovsky","display_name":"Yekaterina (Katie) Chudnovsky","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2023-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Elicio Therapeutics, Inc. DEF 14A 2026-10-09","source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000061-index.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-10-09","last_checked_at":"2026-10-11T00:14:07.386956+00:00"},"headshot_url":null}],"executives":[],"coverage":{"schema_version":"alpha-leadership-coverage-v1","board_roster_scope":"def_14a_current_directors","executive_roster_scope":"NOT_ASSERTED","neo_set_status":"NOT_ASSERTED","board_roster_complete":false,"neo_set_complete":false,"notes":["Empty executives is NOT_ASSERTED, not a complete named-executive-officer set.","Form 4 occupancy is not a DEF 14A board.","Unconfirmed current sec_proxy DEF 14A directors may project. Confirmed is not required.","Unconfirmed current executives with first-party issuer evidence (source_url + effective date) may project.","Company-page directors do not require people.public_profile_enabled.","Completeness compares the latest first-party roster with the public projection; a source older than 180 days is STALE.","Do not remap HONA to HON 0000773840. Do not merge XOM 0000034088 with 0002115436.","Person match is projection-only. Name-only Person merges are forbidden."],"completeness":{"reasons":["NO_LEADERSHIP_SOURCE"],"board_completeness":"NOT_REVIEWED","completeness_schema":"alpha-leadership-completeness-v1","executive_team_completeness":"NOT_REVIEWED"},"parser_bleed_excluded":true,"former_titles_excluded":true,"identity_merge_forbidden":true,"form4_occupancy_is_not_board":true}},"governance":{"summary":"Current confirmed board seats plus verified executive Claims. Committees appear only when membership is stored on a current role.","boundary":"Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. Empty executives is NOT_ASSERTED, not a complete NEO set. Form 4 occupancy is not a DEF 14A board. Chair is never inferred from list order. Person identities are not merged on name.","committees":[{"name":"Audit","canonical_type":"audit","chair":null,"members":[{"display_name":"Carol Ashe","person_slug":"carol-ashe","is_chair":false,"committee_role":"member"}],"source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000061-index.htm","source_type":null,"source_id":"board_seats","note":"Projected from current board_seats committee assignments and chair flags. A combined environment, health, safety, and technology name uses the esg and technology flags. Chair is not inferred from list order. Person identities are not merged on name."},{"name":"Compensation","canonical_type":"compensation","chair":"Carol Ashe","members":[{"display_name":"Carol Ashe","person_slug":"carol-ashe","is_chair":true,"committee_role":"chair"}],"source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000061-index.htm","source_type":null,"source_id":"board_seats","note":"Projected from current board_seats committee assignments and chair flags. A combined environment, health, safety, and technology name uses the esg and technology flags. Chair is not inferred from list order. Person identities are not merged on name."},{"name":"Nominating and Governance","canonical_type":"nominating_governance","chair":null,"members":[{"display_name":"Carol Ashe","person_slug":"carol-ashe","is_chair":false,"committee_role":"member"}],"source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000061-index.htm","source_type":null,"source_id":"board_seats","note":"Projected from current board_seats committee assignments and chair flags. A combined environment, health, safety, and technology name uses the esg and technology flags. Chair is not inferred from list order. Person identities are not merged on name."}],"disclosures":[{"record":"Audit","status":"Extracted","authority":"Issuer proxy / committee disclosure"},{"record":"Compensation","status":"Extracted","authority":"Issuer proxy / committee disclosure"},{"record":"Nominating and Governance","status":"Extracted","authority":"Issuer proxy / committee disclosure"}]},"permissions":{"classification":"open_public_projection","public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false},"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"structured_data":{"@context":["https://schema.org",{"alpha":"https://alpha.ac/ns/","indexMembership":"alpha:indexMembership","indexProvider":"alpha:indexProvider","indexMembershipStatus":"alpha:indexMembershipStatus","indexEffectiveDate":"alpha:indexEffectiveDate","indexAnnouncementDate":"alpha:indexAnnouncementDate","indexRemovalDate":"alpha:indexRemovalDate","lastVerifiedAt":"alpha:lastVerifiedAt","verificationStatus":"alpha:verificationStatus","evidence":"alpha:evidence"}],"@type":"ProfilePage","@id":"https://registry.alpha.ac/companies/elicio-therapeutics-inc#profile","url":"https://registry.alpha.ac/companies/elicio-therapeutics-inc","dateModified":"2026-11-06T04:47:02.533883+00:00","mainEntity":{"@type":"Organization","@id":"https://registry.alpha.ac/companies/elicio-therapeutics-inc#organization","legalName":"Elicio Therapeutics, Inc.","name":"Elicio Therapeutics, Inc.","description":"Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing muta","url":"https://registry.alpha.ac/companies/elicio-therapeutics-inc","addressCountry":"US","indexMembership":[],"member":[{"@type":"OrganizationRole","roleName":"Director","startDate":"2023-01-01","member":{"@type":"Person","name":"Allen R. Nissenson, M.D.","url":"https://registry.alpha.ac/people/allen-r-nissenson-m-d"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2023-01-01","member":{"@type":"Person","name":"Carol Ashe","url":"https://registry.alpha.ac/people/carol-ashe"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2023-01-01","member":{"@type":"Person","name":"Jay Venkatesan","url":"https://registry.alpha.ac/people/jay-venkatesan-ser"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2023-01-01","member":{"@type":"Person","name":"Julian Adams, Ph.D.","url":"https://registry.alpha.ac/people/julian-adams-ph-d"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2023-01-01","member":{"@type":"Person","name":"Robert Connelly","url":"https://registry.alpha.ac/people/robert-connelly"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2023-01-01","member":{"@type":"Person","name":"Robert R. Ruffolo, Jr., Ph.D.","url":"https://registry.alpha.ac/people/robert-r-ruffolo-jr-ph-d"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2023-01-01","member":{"@type":"Person","name":"Yekaterina (Katie) Chudnovsky","url":"https://registry.alpha.ac/people/yekaterina-katie-chudnovsky"}}]},"mainEntityOfPage":"https://registry.alpha.ac/companies/elicio-therapeutics-inc"},"financials":{"kind":"financials","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"ownership":{"kind":"ownership","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented. 13F and N-PX are not beneficial ownership and are never projected here.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"registry_intelligence":{"schema_version":"alpha-registry-intelligence-v1","record_version":"unavailable","subject":"alpha:company:elicio-therapeutics-inc","as_of":"unavailable","recorded_at":"unavailable","availability":"unavailable","records":[],"next_offset":null,"limitations":["Structured intelligence is not currently available. Existing published profile evidence remains accessible."]},"risk_oversight":{"schema_version":"alpha-risk-oversight-v1","subject":"alpha:company:elicio-therapeutics-inc","record_version":"d751713988987e9331980363e24189ce","as_of":"2026-11-06T20:48:46.963906+00:00","recorded_at":"2026-11-06T20:48:46.963906+00:00","availability":"available","complete":true,"records":[],"limitations":["Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording.","An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence."]}},"canonical_source":"aegis_canonical","registry_intelligence":{"schema_version":"alpha-registry-intelligence-v1","record_version":"unavailable","subject":"alpha:company:elicio-therapeutics-inc","as_of":"unavailable","recorded_at":"unavailable","availability":"unavailable","records":[],"next_offset":null,"limitations":["Structured intelligence is not currently available. Existing published profile evidence remains accessible."]},"risk_oversight":{"schema_version":"alpha-risk-oversight-v1","subject":"alpha:company:elicio-therapeutics-inc","record_version":"d751713988987e9331980363e24189ce","as_of":"2026-11-06T20:48:46.963906+00:00","recorded_at":"2026-11-06T20:48:46.963906+00:00","availability":"available","complete":true,"records":[],"limitations":["Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording.","An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence."]}}